Log in
Enquire now
‌

US Patent 10555951 Targeted treatment of leiomyosarcoma

Patent 10555951 was granted and assigned to Eli Lilly and Company on February, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Eli Lilly
Eli Lilly
Current Assignee
Eli Lilly
Eli Lilly
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10555951
Date of Patent
February 11, 2020
Patent Application Number
15560676
Date Filed
April 6, 2016
Patent Citations Received
‌
US Patent 11376259 Targeted treatment of mature T-cell lymphoma
‌
US Patent 11564929 Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
‌
US Patent 11298362 Combination therapy with Notch and CDK4/6 inhibitors for the treatment of cancer
Patent Primary Examiner
‌
Sarah Pihonak
Patent abstract

A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating leiomyosarcoma is provided.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10555951 Targeted treatment of leiomyosarcoma

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.